CJ Bioscience announced today that it will present preclinical data on its novel drug candidate CJRB-201 at the European ...

Thetis Pharmaceuticals LLC (“Thetis”), a clinical-stage company developing TP-317, a first-in-class, small molecule drug ...

Here, the authors show that a Gi-biased S1PR1 agonist, SAR247799, protects the endothelial barrier in IBD models without affecting ... for improving clinical and preclinical IBD studies by ...

Noninvasive monitoring methods, such as enterography and ultrasound, are becoming increasingly recognized as essential tools ...

The drug is being considered for the treatment of inflammatory bowel disease (IBD) and was nominated as a preclinical candidate ... of Insilico's broader R&D model, which relies on its Chemistry42 ...

Preclinical studies in multiple animal models confirm significant improvements ... for the treatment of inflammatory bowel disease (IBD). The company has selected CJRB-201 as the next drug ...

"The preclinical results demonstrate ... Therapy in Inflammatory Bowel Disease (IBD): Translating Resolvin E1 Activation of BLT1 in Experimental Models to Healthy Volunteers Abstract Number ...